ENCEPUR KIDS 0.75mcg / 0.25ml suspension for injection in pre-filled syringe medication leaflet

J07BA01 tick-borne encephalitis vaccine • Antiinfectives for systemic use | Viral vaccines | Encephalitis vaccines

The tick-borne encephalitis (TBE) vaccine is used to prevent encephalitis caused by the virus transmitted through the bite of infected ticks. This viral disease can cause severe inflammation of the brain and spinal cord, with risks of long-term neurological complications or even death. The TBE virus is endemic in many regions of Europe and Asia.

The vaccine is administered intramuscularly, usually in three doses for primary immunization, followed by booster doses at regular intervals to maintain immunity. It is recommended for individuals living in or traveling to endemic areas, as well as those engaging in outdoor activities in high-risk regions.

Common side effects include pain at the injection site, mild fever, fatigue, and headache. In rare cases, severe allergic reactions may occur.

The TBE vaccine is an essential preventive measure for reducing the risk of infection and protecting public health in affected regions.

General data about ENCEPUR KIDS 0.75mcg / 0.25ml

Substance: tick-borne encephalitis vaccine

Date of last drug list: 01-07-2021

Commercial code: W67661004

Concentration: 0.75mcg / 0.25ml

Pharmaceutical form: suspension for injection in pre-filled syringe

Packing volume: 0,25ml

Product type: original

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: GSK VACCINES GMBH - GERMANIA

Holder: BAVARIAN NORDIC A/S - GERMANIA

Number: 5405/2013/04

Shelf life: 2 years

Concentrations available for tick-borne encephalitis vaccine

0.25ml, 0.5ml, 0.75mcg/0.25ml, 1.5mcg/0.5ml

Other substances similar to tick-borne encephalitis vaccine